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Abstract
When considering a genetic disease with variable age at onset (ex: dia-
betes, familial amyloid neuropathy, cancers, etc.), computing the individual
risk of the disease based on family history (FH) is of critical interest both for
clinicians and patients. Such a risk is very challenging to compute because:
1) the genotype X of the individual of interest is in general unknown; 2)
the posterior distribution P(X|FH, T > t) changes with t (T is the age at
disease onset for the targeted individual); 3) the competing risk of death is
not negligible.
In this work, we present a modeling of this problem using a Bayesian
network mixed with (right-censored) survival outcomes where hazard rates
only depend on the genotype of each individual. We explain how belief
propagation can be used to obtain posterior distribution of genotypes given
the FH, and how to obtain a time-dependent posterior hazard rate for any
individual in the pedigree. Finally, we use this posterior hazard rate to
compute individual risk, with or without the competing risk of death.
Our method is illustrated using the Claus-Easton model for breast cancer
(BC). This model assumes an autosomal dominant genetic risk factor such
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as non-carriers (genotype 00) have a BC hazard rate λ0(t) while carriers
(genotypes 01, 10 and 11) have a (much greater) hazard rate λ1(t). Both
hazard rates are assumed to be piecewise constant with known values (cuts
at 20, 30, . . . , 80 years). The competing risk of death is derived from the
national French registry.
Keywords: piecewise constant hazard, Bayesian network, belief propagation,
Hardy-Weinberg, Mendelian transmission.
1 Introduction
Complex diseases with variable age at onset typically have many interacting fac-
tors such as the age, lifestyle, environmental factors, treatments, genetic inherited
components. The genetic component is generally composed of one or several genes
including major genes for which a deleterious mutation rises significantly the risk
of the disease and/or minor genes which participation in the disease is moderate
by itself.
The mode of inheritance can be monogenic if a mutation in a single gene
is transmitted or polygenic if mutations in several genes are transmitted. As an
example of a major gene in a complex disease, the BRCA1 gene is well known to be
strongly correlated with ovarian and breast cancer since the 90s (Hall et al., 1990;
Claus et al., 1994). Carriers of a deleterious mutation in BRCA1 gene have a much
higher risk to be affected with relative risks ranging from 20 to 80 but deleterious
mutations in BRCA1 gene only explain 5 to 10 % of the disease (Mehrgou and
Akouchekian, 2016) as many other implicated known or unknown genes exist along
with sporadic cases (cases with no inherited component).
In other rare genetic diseases such as the Transthyretin-related Hereditary
Amyloidosis (THA), no sporadic cases are found and therefore the incidence is
equal to zero among non-carriers and all affected individuals are necessarily car-
riers of a deleterious mutation (Plante-Bordeneuve et al., 2003; Alarcon et al.,
2009).
The family history (FH) of such diseases is often the first tool for clinicians to
detect a family of carriers of a deleterious mutation as any unusual accumulation
of cases in relatives leads to suspect a deleterious allele in the family. With the
appropriate model and computation, the FH can be used to better target the
most appropriate individuals for a genetic testing and / or to identify high-risk
individuals who require special attention (monitoring and/or treatments).
The first challenge to compute such a model comes from the fact that geno-
types are mostly (if not totally) unobserved and that posterior carrier probability
computations must sum over a large number of familial founders’ genotypes con-
figurations. Once such computations are carried out, deriving posterior individual
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disease risk is also a challenging task since the posterior carrier distribution changes
over time and must be accounted for. Finally, for diseases with possibly late age
at onset (e.g. cancer), the competing risk of death is not negligible and must be
accounted for.
A competing risk situation occurs when an event (called a competing event)
precludes the occurrence of the event of interest. This is typically the case for
late-onset diseases as the risk of death is not negligible for advanced age. Ignoring
the risk of death would amount to assume that death cannot happen and would
therefore lead to overestimate the cumulative incidence (the probability of having
the disease before any time point). Famous examples of such situations include
dementia where the patients are of a particularly advanced age and have a high
risk of dying as in Jacqmin-Gadda et al. (2014) or Wanneveich et al. (2016), or
studies on geriatric patients (see for instance Berry et al., 2010).
Classical familial risk models such as Claus-Easton (Claus et al., 1991; Easton
et al., 1993), BOADICEA (Antoniou et al., 2004), or the BayesMendel models
(BRCAPRO, MMRpro, PancPRO and MelaPRO, see Chen et al., 2006) do not
take into account the competing event of death. As a result, it is likely that
individual predictions will tend to be overestimated from these models (De Pauw,
2012). The main result of the present work is that we show how to derive individual
risk predictions from the family history while taking into account the competing
risk of death, which is a new contribution to the best of our knowledge.
Another interesting point is that, unlike most similar publications, we here
provide all the necessary details to integrate the likelihood over the unobserved
genotypes and to compute posterior genotype distributions using Bayesian network
and sum-product algorithms. One should not that these models and algorithms
clearly are often used in the context of genetics (see Lauritzen, 1996; O’Connell
and Weeks, 1998; Fishelson and Geiger, 2002; Lauritzen and Sheehan, 2003; Palin
et al., 2011, for a few examples), but rarely fully detailed (see Chen et al., 2006,
for example).
It should also be noted that the genetics community usually prefers to rely on
simple peeling algorithms rather than Bayesian network for pedigree computations
but the two concepts are in fact totally equivalent, and the sum-product algorithm
presented in this paper can indeed be seen as a simple Bayesian network based
reformulation of the most general peeling-based algorithm developed so far (Totir
et al., 2009).
The paper is organized as follows: firstly, in Section 2.1 we introduce a formal
generic Bayesian network model adaptable to any genetic disease with variable age
at onset. Secondly, in Section 2.2, we provide in this context all the necessary de-
tails to carry belief propagation on this model, and express the marginal posterior
carrier distribution using Bayesian network’s potentials. Thirdly, in Section 2.3, we
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give closed-form formulas for the posterior individual disease risk, and introduce
a simple numerical algorithm allowing to take into account the competing risk of
death. Finally, in Section 3, all the methods are illustrated with the Claus-Easton
model for breast cancer using the disease model and the parameters of Claus et al.
(1991); Easton et al. (1993). In particular, individual predictions derived by taking
into account the competing risk of death or ignoring it are compared, which em-
phasizes the importance of properly taking into account competing risk of death
in such models.
2 Materials and Methods
In this section, we first introduce our model (Section 2.1) as a Bayesian network.
We next explain how to perform belief propagation in order to obtain posterior
carrier distributions (Section 2.2). Finally, we provide all the details needed to
derive disease risks predictions from these posterior distributions, including taking
into account the competitive risk of death (Section 2.3).
2.1 The Bayesian Network
We consider a total of n (related) individuals. With I = {1, . . . , n}, we denote
by F ⊂ I the subset of the founders (i.e. individuals without ancestors in the
pedigree) and we denote by I \ F the set of non-founders (i.e. with ancestors
in the pedigree). Let X = (X1, . . . , Xn) ∈ {00, 01, 10, 11}n be the genotypic
distribution1 of the whole family, where Xi denotes the genotype of Individual i.
Let T = (T1, . . . , Tn) ∈ Rn be the time vector representing the age at diagnosis of
all individuals. The joint distribution of (X,T ) is given by:
P (X,T ) =
∏
i∈F
P(Xi)
∏
i∈I\F
P
(
Xi|Xpati , Xmati
)
︸ ︷︷ ︸
genetic part
×
∏
i∈I
P (Ti|Xi)︸ ︷︷ ︸
survival part
(1)
which corresponds to the definition of a Bayesian Network (BN). See Koller and
Friedman (2009) for more details. The genetic part of Eq. (1) only relies on the
“classical” Mendelian assumption that the distribution of a non-founder genotype
only depends on the parental genotypes. The survival part makes the strong
assumption that all Ti are conditionally independent given Xi. This assumption
is clearly not true when considering any other familial effect on the disease (e.g.
polygenic effect, environmental exposure, etc.) which is often taken into account
1For the sake of simplicity, we consider here a simple bi-allelic gene but multi-allelic genes
can obviously be easily considered.
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using a familial random effect (often called frailty in the survival context). Such
familial random effect is for example assumed to account for a polygenic effect
in the BOADICEA model (Antoniou et al., 2002, 2004). Note that for the sake
of simplicity, the symbol “P” corresponds through the whole paper either to a
probability measure or to a density.
The extension of the present model to frailty models such as BOADICEA is
clearly possible and, in many ways, quite straightforward. However, for the sake of
simplicity, we focus here on a simpler model and will briefly discuss the extension
in the conclusion section. However, even with the strong assumption that Ti
only depends on Xi, since (the basically unobserved) X has a strong correlation
structure within the pedigree, so does T .
We can see on Fig. 1 an example of a moderate size (hypothetical) family with
a severe history of breast and ovarian cancer. This family has a total of n = 12
individuals with F = {1, 2, 3, 4} and I \ F = {5, 6, 7, 8, 9, 10, 11, 12}. There is no
inbreeding (mating between individuals with a common ancestor) in this family
but a mating loop (two families joined more than once by mating) due to the two
brothers of the first nuclear family having children with two sisters of the second
nuclear family. Such looped pedigree can be tricky to represent and this explains
why Individual 7 appears twice (with an identity link) in Fig. 1.
One should note that loops in pedigree are not the same as cycles in the
Bayesian networks framework in the sense that the underlying conditional de-
pendence structure of the model remains a proper directed acyclic graph even in
the presence of pedigree with loops.
Genetic Part. For the genetic part, we assume that founders’ genotypes are
distributed according to the Hardy-Weinberg distribution with disease allele fre-
quency f . It means that for any founder i ∈ F we have P(Xi = 00) = (1 − f)2,
P(Xi = 01) = P(Xi = 10) = f(1 − f), and P(Xi = 11) = f 2. This assumption is
extremely frequent in family genetics and usually reasonable since it corresponds
to the stationary distribution we observe in a population under mild assumptions.
However, one should note that other distributions can easily be considered if nec-
essary (e.g. genotype 11 forbidden because it is lethal). For the non-founder we
simply assume a Mendelian transmission of the alleles, but unbalanced transmis-
sion patterns can also be considered.
The genetic part of the model can also be easily extended to account for various
constraints. For example, the presence of monozygous twins, say individuals i and
j, only requires one to add an identity variable between the two genotypes: Ii,j ∈
{0, 1} such as P(Ii,j|Xi, Xj) = 1{Xi = Xj}. Genetic tests (including error or not)
can also be incorporated as additional variables Gi such as P(Gi|Xi) corresponding
to the test specificity and sensibility. Finally, assuming lethal genotypes (e.g.
5
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Figure 1: A hypothetical family with a severe FH of cancer. Squares correspond
to males, circles to females, and affected individual are filled in black. Individual
id on the top-right of the nodes, personal history of cancer (UN=UNaffected;
BC=Breast Cancer; OC=Ovarian Cancer) on the bottom-right. The dashed line
represents an identity link used to represent the mating loop (due to the mating
between individuals 5/8 and 6/7) between brothers 5 and 6, and sisters 7 and 8.
genotype 11) is done straightforwardly by setting to 0 the probability of carrying
such genotype. This is equivalent to working conditionally on {Xi 6= 11 for all i}
which obviously alter all genotype distributions, including Hardy-Weinberg for
founders.
Survival Part. We place ourselves in the classical survival framework, denoting
by λ(t) the (time dependent) hazard function, by S(t) the survival function defined
as S(t) = exp(−Λ(t)) where Λ(t) = ∫ t
0
λ(u)du is the cumulative hazard.
We assume an autosomal dominant model where non-carriers have a disease
incidence λ0(t) and carriers have a disease incidence λ1(t). This simple assumption
results in the following expression of the survival part of the model:{
P(Ti > t|Xi = 00) = S0(t) and P(Ti = t|Xi = 00) = S0(t)λ0(t)
P(Ti > t|Xi 6= 00) = S1(t) and P(Ti = t|Xi 6= 00) = S1(t)λ1(t) . (2)
As explained above, the symbol “P” corresponds to a (conditional) probability
measure for the event {Ti > t} and to a density for the punctual event {Ti = t}.
For example, in the context of the THA, non-carriers cannot be affected (λ0(t) ≡
0) and only carriers have an age-dependent incidence. In the context of breast can-
cer, λ0(t) might be the incidence for non BRCA carriers and λ1(t) the incidence
for BRCA carriers (BRCA1 or BRCA2).
Of course the simple model suggested in Eq. (2) can easily be extended to
account for other genetic models (e.g. recessive, additive, gonosomal (i.e. non-
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autosomal), with parent-of-origin effect, etc.) as well as for any known covariates
(e.g. BMI, smoking, other diseases, etc.) using a classical proportional hazard
model.
Hazard rates λ0(t) and λ1(t) are typically described by the literature as piece-
wise constant hazards (PCHs), but our model allows for any parametric or non-
parametric shape as long as hazard rates are provided (e.g. hazard rates of Weibull
distributions, Gaussian survival, etc.).
2.2 Carrier Risk
For all individual i let us denote by PHi his/her personal history of the disease.
In the case where Individual i was diagnosed with the disease at age ti we have
PHi = {Ti = ti}. If Individual i was unaffected at age ti (age at the last follow-
up), the variable Ti is right-censored and we have PHi = {Ti > ti}. From now
on, we denote by FH the family history of the disease. This includes the personal
history of all individuals and all possible additional constraints or informations
(e.g. monozygous twins, genetic tests, lethal alleles, etc.). Formally, we can define
FH = ∪i(PHi ∪ {Xi ∈ Xi}) where Xi ⊂ {00, 01, 10, 11} is the subset of allowed
values for Xi (e.g. Xi = {00, 01, 10} if we know that the genotype 11 is lethal,
Xi = {00} if we know that a particular individual is a non-carrier, etc.). Even with
genetic testing, it is essential to understand that X is, at best, partially observed.
Indeed, even with a (hypothetical and unrealistic) 100% specificity/sensitivity test,
a positive heterozygous carrier status cannot distinguish between genotypes 01 and
10. Moreover, genetic tests are in general only available for a few individuals in the
whole pedigree. Accounting for the unobserved genotypes is therefore of utmost
importance.
Following the classical BN notations, we write the so-called evidence P(FH) as
the simple following sum-product of potentials :
P(FH) =
∑
X1
. . .
∑
Xn
n∏
i=1
Ki
(
Xi|Xpai
)
(3)
where the potentials are defined by:
Ki
(
Xi|Xpai
)
= P(PHi|Xi)×
{
P
(
Xi|Xpati , Xmati
)
if i ∈ I \ F
P (Xi) if i ∈ F (4)
where P(PHi|Xi) is either P(Ti = ti|Xi) or P(Ti > ti|Xi) and can be obtained
through Eq. (2). Note that pai ⊂ I denote the parental set of Individual i (empty
for founders), and that XJ = (Xj)j∈J for any J ⊂ I. As explained above, any
additional information or constraint might and should be added directly into the
potentials.
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SinceX has 4n possible configurations in the worst case, it is clearly impossible
to simply enumerate these configurations even for moderate size pedigrees (e.g.,
for n = 10 or n = 20). We therefore need a more efficient algorithm to com-
pute Eq. (3). An efficient solution is provided by the Elston-Stewart algorithm
(Elston et al., 1992) in the particular (and frequent) case where the pedigree has
no loop. The basic idea is to eliminate variables from the sum-product (peeling
in the Elston-Stewart literature) from the last generations up to the oldest com-
mon ancestor. The resulting complexity O(n× 43) clearly allows one to deal with
arbitrary pedigree size as long as there is no loop.
Unfortunately, loops (inbreeding or mating) are not totally uncommon in pedi-
grees and therefore have to be accounted for. A simple extension of the Elston-
Stewart algorithm consists in using loop breakers: working conditionally to a few
number of key genotypes that can be considered as duplicated individuals with
known genotypes in a pedigree with no loop. For example, in Fig. 1, Individual 7
is a possible loop breaker. By performing a classical Elston-Stewart algorithm for
each genotypic configuration of the loop breakers, P(FH) can be computed with
complexity O(n× 4`+3) where ` is the number of loop breakers.
In the context of Bayesian networks, computing P(FH) (and, in fact, the whole
P(X,FH) distribution) is typically done through belief propagation (BP)2 with a
O(n× 4k) complexity where k is the tree-width of the graphical model (see Koller
and Friedman, 2009, for more details). For a pedigree with no loop, k = 3 and
the BP complexity is strictly the same than Elston-Stewart, but for more complex
pedigrees, k usually increases much slower than `+ 3 and, as a result, BP is often
dramatically faster than Elston-Stewart with loop breakers.
In order to achieve this, BP basically eliminates variables from the sum-product
of Eq. (3) in a suitable order. In that sense, it is very similar to the notion of
cutset long used to compute likelihoods in complex pedigrees (see Lange et al.,
2013, for a recent reference on the MENDEL package). But BP has the noticeable
advantage to allow obtaining the full posterior distribution P(X|FH) for the same
algorithmic complexity while likelihood-based approaches need to repeat many
cutset eliminations to achieve the same results. As a consequence, it should not be
surprising to see that, in parallel with the classical genetic literature (Elston et al.,
1992; Kruglyak et al., 1996; Lange et al., 2013) many authors have been using BP
and BN to deal with genetic models (Lauritzen, 1996; O’Connell and Weeks, 1998;
Fishelson and Geiger, 2002; Lauritzen and Sheehan, 2003; Palin et al., 2011).
Let us finally point out that the genetics community has put considerable
efforts in developing Elston-Stewart algorithms for any Bayesian network counter-
part, claiming that peeling-based algorithms are more natural for geneticists than
junction-tree based ones. Note however that the most general version of these
2Also called sum-product algorithm.
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Figure 2: Junction tree of our hypothetical family with the following elimination
order: X9, X10, X11, X12, X1,2, X5, X6, X3,4,7,8.
peeling algorithms (Totir et al., 2009) is in fact exactly equivalent to the classical
junction-tree based forward/backward algorithm presented below.
For completeness, we will now briefly recall all the minimal necessary results
to implement BP in the context of our model. We nevertheless encourage the
interested reader to refer to more classical references like Lauritzen and Sheehan
(2003) or Koller and Friedman (2009) for more details.
Variable Elimination and Junction Tree. As an example, we consider the
pedigree of Fig. 1 and want to compute P(FH) by successive variable elimination.
We use the following elimination order: X9, X10, X11, X12, X1,2, X5, X6, and
X3,4,7,8. Here follow the quantities obtained in the process:
F1(X3,4) =
∑
X9
K3(X3)K4(X4)K9(X3,4,9); F2(X5,8) =
∑
X10
K10(X5,8,10);
F3(X6,7) =
∑
X11
K11(X6,7,11); F4(X6,7) =
∑
X12
F3(X6,7)K12(X6,7,12);
F5(X5,6) =
∑
X1,2
K1(X1)K2(X2)K5(X1,2,5)K6(X1,2,6); F6(X6,8) =
∑
X5
F2(X5,8)F5(X5,6);
F7(X7,8) =
∑
X6
F4(X6,7)F6(X6,8); P(FH) =
∑
X3,4,7,8
F1(X3,4)F7(X7,8)K7(X3,4,7)K8(X3,4,8).
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We therefore can obtain P(FH) by considering only 6× 43 + 2× 44 = 896 config-
urations over the 412 ' 16.8 × 106 total number of X configurations. Note that
a memory bounded version of the variable elimination exists, see Darwiche (2001)
for more details.
Fig. 2 is a graphical representation of this particular sequence of elimination
and is also a junction tree defined as a set of K cliques C1, . . . , CK with Cj ⊂
{X1, . . . , Xn} with the following properties:
i) tree: each clique j is connected to a a subsequent clique toj ∈ {j + 1, . . . , K}
(toK = root by convention). We also define fromk = {j, toj = k} (from1 = ∅)
and Sj = Cj ∩ Ctoj (with the convention that SK = ∅).
ii) covering: for all i ∈ {1, . . . , n} it exists a j such as {Xi, Xpai} ⊂ Cj. We then
define ofi = min{j, (Xi, Xpai) ⊂ Cj} and C∗j = {Xi ∈ Cj, ofi = j}.
iii) running intersection: for all i ∈ {1, . . . , n} the subgraph formed by {Cj, Xi ∈
Cj} (and the from/to relationships) is a tree.
In the graph theory, junction trees are used as an auxiliary structure for many
applications (e.g. graph coloring). The proof that any elimination sequence gives
a junction tree can be found in Koller and Friedman (2009). The tree-width of an
elimination sequence / junction tree is defined as the size of its largest clique. Find-
ing the elimination sequence with the smallest tree-width is NP-hard in general,
but many heuristics are available (Koller and Friedman, 2009). The elimination
order of Fig. 2 has been obtained using the well-known minimum fill-in heuristic.
Belief Propagation. We assume that a suitable elimination order / junction
tree has been obtained. For all j ∈ {1, . . . , K} we hence define the potential of
clique Cj as Φj(Cj) =
∏
Xi∈C∗j Ki
(
Xi|Xpai
)
and we have the following result:
Theorem 1. (posterior distribution) For all i ∈ {1, . . . , n}, let k = ofi and we
have:
P(Xi,FH) =
∑
Ck\{Xi}
{ ∏
j∈fromk
Fj(Sj)× Φk(Ck)×Bk(Sk)
}
where the forward quantities are defined for k = 1, . . . , K by:
Fk(Sk) =
∑
Ck\Sk
{ ∏
j∈fromk
Fj(Sj)× Φk(Ck)
}
and the backward quantities are defined by BK(SK = ∅) = 1 (convention) and for
k = K, . . . , 2, for all i ∈ fromk:
Bi(Si) =
∑
Ck\Si
{ ∏
j∈fromk,j 6=i
Fj(Sj)× Φk(Ck)×Bk(Sk)
}
.
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Proof. See Appendix A.
Using Theorem 1, it is therefore possible to obtain P(FH) and all P(Xi|FH) by
just recursively computing once all forward and backward quantities.
2.3 Disease Risk
While the previous section covered the computation of the posterior probability
P(Xi|FH) for all individuals in the pedigree, we now focus in this section on com-
puting individual posterior disease risks, with or without the competing risk of
death.
Risk without competing events. We consider an individual i with a posterior
carrier probability pi at age τ , that is pi = P(Xi 6= 00|FH, Ti > τ). Conditionally
to the family history, we denote the survival and hazard functions respectively
by S and λ such that, for t ≥ τ , S(t) = P(Ti > t|FH, Ti > τ) and S(t) =
exp(− ∫ t
τ
λ(u)du). We have the following result.
Theorem 2. For any t ≥ τ , we have:
S(t) = pi
S1(t)
S1(τ)
+ (1− pi) S0(t)
S0(τ)
P(Xi 6= 00|FH, Ti > t) = 1
S(t)
pi
S1(t)
S1(τ)
λ(t) =
1
S(t)
[
pi
S1(t)
S1(τ)
λ1(t) + (1− pi) S0(t)
S0(τ)
λ0(t)
]
(5)
Proof. See Appendix B.
Risk with death as a competing event. As explained in the introduction,
death precludes the occurence of the disease. This needs to be taken into account
by defining the hazard rate of the disease conditionally to the fact that both
disease and death have not occurred yet. From a statistical point of view, such a
situation can be seen as a competing risk situation or as an illness-death model;
see Andersen et al. (1993) or Andersen and Keiding (2012) for a presentation of
such models. We define T ∗ as the minimum between age at disease onset and age
at death and we keep the notation T to denote the age at disease onset. Given an
individual i with a family history FH, its hazard rate for the disease is defined as
λα(t) = lim
∆t→0
P(t ≤ Ti < t+ ∆t|T ∗i ≥ t,FH)
∆t
11
We denote by λβ and Sβ the hazard and survival functions of T
∗
i (conditionally
to the family history) and we assume that λα and λβ are piecewise constants with
common cuts τ = c0 < c1 < . . . < cN (that is λα(t) = αj and λβ(t) = βj for
t ∈]cj−1, cj]).
Lemma 3. For j = 1, . . . , N , t ∈]cj−1, cj], we have
P(Ti ≤ t|Ti > cj−1,FH) =
∫ t
cj−1
λα(u)Sβ(u)du =
αj
βj
[Sβ(cj−1)− Sβ(t)]
Proof. See Appendix B.
Practical computations. We assume that one individual has a carrier prob-
ability pi at age τ (his age without the disease in the FH). We denote by λdeath
his/her hazard of death. Then the posterior disease risk with the competing risk
of death can be computed through the following steps:
1) choose a fine enough discretization τ = c0 < c1 < . . . < cN = tmax (ex: all
cj − cj−1 = 0.1 year);
2) compute αj = λα(cj) using Eq. (5);
3) compute βj = αj + λdeath(cj);
4) then the marginal posterior probability of being diagnosed with the disease
before age ck, in the presence of death as a competing risk, is given for k =
1, . . . , N by:
P(Ti 6 ck|FH) =
k∑
j=1
αj
βj
[Sβ(cj−1)− Sβ(cj)] .
3 Results and Discussion
3.1 The Claus-Easton Model
In order to illustrate our method, we will use the model of illness and the param-
eters of the Claus-Easton model developed from the Cancer and Steroid Hormone
Study in the 90s (Claus et al., 1991; Easton et al., 1993).
The Claus-Easton model is a classical genetic model composed of a genotypic
part and a phenotypic part with only the family history (FH) as covariate. It
assumes an autosomal dominant mode of inheritance, and a piecewise constant
hazard rate by steps of 10 years. The penetrance (F (t) = 1 − S(t)) and the
12
20− 30 30− 40 40− 50 50− 60 60− 70 70− 80 > 80
non carriers 2.00 26.04 112.94 139.94 235.17 232.16 232.03
carriers 168.35 1391.49 3153.21 3222.22 3281.25 3289.86 3286.43
relative risk 84.17 53.44 27.92 23.03 13.95 14.17 14.16
Table 1: Annual incidence (for 100,000) of breast cancer (BC) for carriers/non-
carriers and relative risks by age (in years) in the Claus-Easton model.
20− 30 30− 40 40− 50 50− 60 60− 70 70− 80 80− 85
23.85375 46.86641 130.5396 308.9539 599.914 1493.6 3845.406
85− 90 90− 95 95− 99 99− 100 100− 101 101− 102 102− 103
8114.203 16400.99 27912.22 35644 38696.22 43033.07 45647.85
Table 2: Annual female death incidence (for 100,000) by age (in years) in the
metropolitan French population between 2012 and 2014 (INED, 2017).
density (f(t) = λ(t)S(t)) are given in Table 2 from Easton et al. (1993) for both
carriers and non-carriers at ages 25, 35, . . . , 85. The hazard rates can therefore be
derived from these data using the formula λ(t) = f(t)/(1 − F (t)). The results of
these computations are given in Table 1. The frequency of the mutated allele has
been estimated at f = 0.0033 (Claus et al., 1991). The death incidences needed
in the competing risk section are given in Table 2.
Figure 3 presents the incidence and survival for BC (carriers and non-carriers)
as well as death. We can notice that the breast cancer incidences in carriers are
always much higher than in non-carriers at any age and the relative risk between
carriers and non-carriers is especially large (RR > 50) before age 40 (see Table 1)
but then decreases with aging. We notice that the death incidence stays above
the BC incidence for non-carriers at all ages and exceeds even the BC incidence
for carriers from age 80. This shows the importance of taking it into consideration
especially over a certain age.
3.2 Carrier Risk
In this section we will use the belief propagation in Bayesian networks to ob-
tain the posterior distribution of individual genotypes given the FH. We get the
posterior probabilities of each genotype (non-carrier, heterozygous carrier with a
paternal mutated allele, heterozygous carrier with a maternal mutated allele and
homozygous carrier).
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Figure 3: Left-panel: annual (female) death incidence and annual non-
carrier/carrier breast cancer incidence. Right-panel: death survival and percentage
of non-carrier/carrier individuals without diagnosed breast cancer.
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Figure 4: Posterior probabilities for the carrier genotypes of each individual (Indi-
vidual 1 to 12) in our hypothetical family (Figure 1). The posterior probability of
being a paternal carrier P(X = 10|FH) (resp. maternal carrier P(X = 01|FH)) is
colored in black (resp. in grey). The deleterious allele being very rare in the gen-
eral population (f = 0.33%), the probability of the monozygous carrier genotype
is almost zero for each individual and it is therefore not represented here.
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Figure 4 represents the marginal posterior probability P(Xi = x|FH) for all
individuals i and for x = 10 (paternal carrier) and x = 01 (maternal carrier). Note
that the posterior probability of the monozygous carrier genotype (x = 11) being
almost zero for each individual, it is not shown here. The posterior probability of
the non-carrier genotype can be easily deduced.
We can notice that the probabilities of being a non-carrier for 1, 3, 4, 7, 8 and 9
are all by far the highest despite the severe phenotype of relatives (granddaughter,
niece or daughter). This result is consistent with the personal history of Individual
2 (ovarian cancer at age 51) which points her out as the most likely origin of the
mutation in the family. Let us note that since we have no additional information on
the ancestors of Individual 2, it is impossible to determine whether her mutation
was transmitted by her father or her mother. As a consequence, the posterior
carrier probability is equally shared between the paternal and maternal carrier
genotypes.
Considering the severe personal history of cancer of Individuals 10 and 11,
the most likely situation would be that they both received the mutation of their
grandmother through their respective fathers (Individuals 6 and 5 respectively).
The posterior probabilities are clearly consistent with this scenario: Individuals 5
and 6 have a probability of ' 90% to be maternal carriers, and Individuals 10 and
11 have similar probabilities to be paternal carriers. Note that Individual 12, being
unaffected at age 37 (which is not very informative) basically have 50% chance to
have received the mutation from her father.
Figure 5 shows some examples of the variations of the posterior marginal distri-
bution of the genotypes in a same family structure according to different FH. We
first notice that with no information (FH1) the posterior probabilities are exactly
those of the general population: P(Xi 6= 00|FH1) = 1− (1− f)2 ' 0.0066.
Note that Individual 2 has a severe personal history of cancer (ovarian cancer
at age 51) in all other examples. As a consequence, Individual 1, as a male with no
personal history of cancer, is mostly totally uninformative therefore not included
in the forthcoming analyses.
Individual 4 having no children, she is independent from the rest of the family
conditionally to her phenotype and her parent’s genotype. With no information
about her phenotype in any FH, her probability of being a carrier is therefore
almost half her mother’s one in each FH (because her father is almost uninforma-
tive). If we compare the posterior distribution of the genotype of Individual 3 in
FH2, FH3 and FH4, we can notice that the ovarian cancer of her mother which
increased her mother’s probability of being a carrier raises her probability of being
a carrier (FH2). A protective information about her phenotype such as no cancer
until age 61 lowers her posterior probability of being a carrier (FH3). On the
contrary, the cancer at young age of her daughter which increases her daughter’s
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Figure 5: Posterior marginal carrier distribution for a total of 6 FH with increasing
degree of severity on the same pedigree structure with 6 individuals. Dashed line
represent half the marginal carrier probability of Individual 2.
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probability of being a carrier raises her own probability of being a carrier (FH4-6).
We also notice the causal relationships in a whole branch of the family with the
transmission between Individuals 2, 3 and 6 of the deleterious allele being highly
probable which raises the probability of being a carrier for Individual 3 even in
the presence of a protective phenotype (unaffected at age 61) in FH4.
We finally observe the influence of the spouse’s genotype when having children
(FH5). The higher risk of being a carrier for Individual 5 (because of his cancer
at age 72) strongly decreases the carrier probability of his spouse (in comparison
with FH4) since the paternal origin of the disease mutation naturally becomes
the most likely event. On the other side, the increase of risk for Individual 3
when suppressing her protective phenotype (FH6) also has a consequence on the
marginal posterior distribution of her spouse in lowering his probability of being
a carrier as his participation in the risk for their daughter is lowered.
To summarize, one’s probability of being a carrier mainly depends on: 1) one’s
probability of having at least one carrier parent, which is correlated to the history
of cancer of one’s ancestors; 2) one’s probability of having transmitted the mutation
to one’s offspring which is correlated to the history of cancer of one’s descendant
relatives and one’s spouse probability of being a carrier.
Remark: As introduced in the “Disease Risk” section, we know that poste-
rior carrier probabilities should decrease with time for unaffected individuals. For
example, if we assume that Individual 4 is unaffected at age 40 in FH6, her prob-
ability of being a carrier is 24%. If she stays unaffected up to age 60 (resp. age
80), her probability of being a carrier decreases to 15% (resp. 8.5%).
Table 3 gives a practical illustration of the dependence and conditional inde-
pendence in a trio grandparent - parent - child. We compare the posterior joint
distribution and the product of the posterior marginal distributions of genotypes
X2 and X6 in FH4 with various information on X3. We can see that these two
quantities are not equal when X3 is not observed while they are exactly the same
when X3 is fixed. This example demonstrates how X2 and X6 are not conditionally
independent given FH but they are, conditionally to FH and X3. Note that when
X3 = 11, the mutation is necessarily found in both parents (Individual 1 and 2)
as well as in her daughter (Individual 6).
3.3 Cancer Risk
As in Section 2.3 we now consider a female individual i who is unaffected at age
τ (i.e. {Ti > τ} ⊂ FH) and denote by pi = P(Xi 6= 00|FH) its posterior carrier
probability. The purpose of this section is to compute the posterior risk of cancer
for this individual (with or without the competing risk of death). As previously
explained, these risks only depend on pi and τ .
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X2/X6 NC/NC NC/C C/NC C/C
FH4
marginal 0.0371306 0.1551811 0.1559446 0.6517438
joint 0.1443102 0.0480015 0.0487650 0.7589233
FH4 and X3 = 10
marginal 0.0092840 0.7741949 0.0025657 0.2139554
joint 0.0092840 0.7741949 0.0025657 0.2139554
FH4 and X3 = 01
marginal 0.0000000 0.0000000 0.0118497 0.9881503
joint 0.0000000 0.0000000 0.0118497 0.9881503
FH4 and X3 = 11
marginal 0.0000000 0.0000000 0.0000000 1.0000000
joint 0.0000000 0.0000000 0.0000000 1.0000000
Table 3: product of the posterior marginal probabilities P(X2|FH)P(X6|FH) and
joint posterior probability P(X2, X6|FH) in the context of known and unknown
X3. NC: non-carrier; C: carrier.
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Figure 6: Individual risk of breast cancer without the competing risk of death and
for various pi and τ
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Figure 7: Posterior probabilities of being a carrier according to the time for Indi-
viduals 3 and 4 in FH4 assuming Individual 4 is 52 at the time of the censoring.
Figure 6 represents the individual risk of breast cancer up to age 1003 without
the competing risk of death and variant pi and τ . We can see that the individual
risk of BC rises as pi increases and τ decreases. This result is quite intuitive as the
younger a patient is, the longer she will be at risk until age 100; the greater her
probability of carrying a deleterious allele, the greater her risk to develop a cancer.
As introduced in the previous section the probability of being a carrier for
an unaffected individual decreases with time if she stays unaffected. Assuming
Individual 4 was 52 in FH4, Figure 7 shows the evolution of the probability of
being a carrier for Individual 3 and Individual 4 in FH4. As they stay unaffected
we can clearly see the decrease of this probability which has to be taken into
account in the computation of the individual risk of breast cancer over time (see
Section 2.3).
As explained in Section 2.3, computing risk with the competing risk of death
requires a numerical discretization of age by a fixed step ∆t. In order to calibrate
∆t we used ∆t = 0.01 as a reference, and observed that ∆t = 0.1 is a reasonable
balance between accuracy and computational efficiency (data not shown).
Figure 8 represents the individual risk of breast cancer for Individual 7 (pi =
3Note that we obtain qualitatively similar results with a lower age limit (e.g. age 80), but
quantitative results are more illustrative with age 100.
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Figure 8: Individual risk of breast cancer with and without the competing risk of
death for individual 7 and 12 of our hypothetical family from τ to 100 years with
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Figure 9: Difference (in percentage) between the individual risk of breast cancer
up to 100 years without and with the competing risk of death for various pi and τ .
Specific values pi = 76.59% and τ = 61 are given by the dashed lines.
0.553% and τ = 62 years) and Individual 12 (pi = 44.6% and τ = 37 years) in
our hypothetical family from τ to 100 years with and without taking into account
the competing risk of death. We can see that the difference between the two
curves for each individual is increasing with the age. The age from which the
difference becomes significant varies with the couple (pi, τ). We also observe that
the individual risk of breast cancer eventually reaches a plateau which corresponds
to the point where the incidence of breast cancer becomes negligible compared to
the incidence of death in the elderly.
Quantitatively, the importance of taking into account the competing risk of
death is pointed out in the Figure 9 which represents the difference between the
individual risk of breast cancer up to the age of 100 years for variant couples (pi,
τ). For example for Individual 3 in FH4 (pi = 76.59%, τ = 61, see Figure 5), the
error while calculating her individual risk of breast cancer up to the age of 100
years reaches almost 14 %. If it is clear that the competing risk of death can have
a limited effect on the global risk of cancer for certain couples (pi, τ) its effect is
never totally negligible, and since we provide a rigorous way to take it into account
we strongly advocate its use in all circumstances.
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4 Conclusions
We presented here a general model for genetic disease with variable age at on-
set. This model, a Bayesian network, combines classical genetic modeling with
survival analysis. In order to deal with the (mostly) unobserved genotypes, we
first explained in detail how belief propagation can be used to perform likelihood
and posterior probability computations. Secondly, we focused on the challenging
problem of computing posterior individual disease risks, with or without taking
into account the competing risk of death. Finally, we illustrated theses results
with the Claus-Easton model for breast and ovarian cancer. The R source codes
are available upon request for the interested readers.
For the sake of simplicity, we only considered a bi-allelic locus with standard
distribution (autosomal, Hardy-Weinberg, Mendelian allele transmission) but ex-
tensions (e.g. multi-loci, unbalanced allele transmission, lethal genotypes, etc.)
are straightforward. For the survival model, we presented a simple dominant ef-
fect without covariates, but again, extensions to any proportional hazard model
(e.g. recessive, additive, with covariates, etc.) are easy to implement. Incorporat-
ing random effects (at the individual and/or familial level) in the model (like in
the BOADICEA model, see Antoniou et al., 2002, 2004) is clearly also possible,
but slightly more challenging.
Computation of posterior carrier distributions remains almost unchanged ex-
cept for the random effect support which must be discretized (five values are
claimed to be sufficient in the BOADICEA literature) and for the belief propaga-
tion which must be performed once for each of the possible value of the random
effect. For posterior risks, calculations get slightly more complex since the pos-
terior individual hazard must now be integrated over the (changing over time)
posterior joint distribution of the individual genotype and of the random effect.
Basically, all computations are slightly more intensive with random effects, but
most results of Section 2.3 remain very similar.
One of the important limitations of the present work is the fact that we assume
that all model parameters are known. However, it should be noted that likelihood
and conditional likelihood might be easy to compute through the belief propagation
which means that we basically provide all the necessary means to estimate the
model parameters from actual data. In that context, it is nevertheless critical to
deal efficiently with ascertainment issues: the fact that the family ending up in the
database are usually precisely the one with the most severe disease family history.
But standard methods like the PEL (Alarcon et al., 2009), which basically are
conditional likelihood computations, are known to deal relatively well with the
problem.
In order to take into account the competing risk of death, we used death from
all causes, which was obtained from registry data (INED, 2017). However, only
22
death without cancer precludes the onset of cancer and we are not interested into
death from all causes. Since registry data usually do not report the causes of
death it is a difficult task to estimate the risk of death without cancer. This
has been studied for instance in Wanneveich et al. (2016) through a illness-death
model, using registry data and differential equations to model the specific causes
of death. Nevertheless, it is very likely that the gain in terms of predictions would
be minor as mortality from all causes is likely to be close to mortality without
cancer.
Further work includes all the extensions described above (e.g. more complex
genetic model, genetic tests, familial random effects, etc.) as well as the develop-
ment of a clinical web application for the Claus-Easton model in close collaboration
with the cancer genetics department of the Institut Curie. From the methodologi-
cal point of view, we plan to focus on the computation of more complex posterior
distribution like the number of carriers in any subgroup of individuals and/or the
familial posterior risk (time before any family member at risk is diagnosed).
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A Proofs for the Carrier Risk Section
For all k ∈ {1, . . . , K} we recursively define: uk = {k} ∪j∈fromk uj, Uk = ∪j∈ukCj,
and Vk = ∪j /∈ukCj. Then we can compute the so-called forward and backward
quantities over any separator Sj = Cj ∩ Ctoj :
Fj(Sj) =
∑
Uj\Sj
∏
Xi∈U∗j
Ki
(
Xi|Xpai
)
and Bj(Sj) =
∑
Vj\Sj
∏
Xi∈V ∗j
Ki
(
Xi|Xpai
)
where U∗j = {Xi ∈ Uj, ∃k ∈ uj, ofi = k} and V ∗j = {Xi ∈ Vj,∃k /∈ uj, ofi = k}.
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The key is then to prove that, for all j ∈ {1, . . . , K} we have:
P(Sj,FH) = Fj(Sj)Bj(Sj) (6)
P(Ck,FH) = Φk(Ck)×
∏
j∈fromk
Fj(Sj)×Bk(Sk). (7)
For proving Eq. (6), we start by noticing that the JT (Junction Tree) properties
(Koller and Friedman, 2009) give: {X1, . . . , Xn} \ Sj = (Uj \ Sj) unionmulti (Vj \ Sj) and
{X1, . . . , Xn} = U∗j unionmulti V ∗j (both being disjoint unions). We therefore have:
P(Sj,FH) =
∑
Uj\Sj
∑
Vj\Sj
∏
Xi∈U∗j
Ki
(
Xi|Xpai
) ∏
Xi∈V ∗j
Ki
(
Xi|Xpai
)
=
∑
Uj\Sj
∏
Xi∈U∗j
Ki
(
Xi|Xpai
)
︸ ︷︷ ︸
Fj(Sj)
×
∑
Vj\Sj
∏
Xi∈V ∗j
Ki
(
Xi|Xpai
)
︸ ︷︷ ︸
Bj(Sj)
the factorization between the first and second equation being possible thanks to the
fact that
(
∪Xi∈U∗j {Xi, Xpai}
)
∩
(
∪Xi∈V ∗j {Xi, Xpai}
)
= Sj (JT properties again).
The proof is basically the same for Eq. (7) using {X1, . . . , Xn}\Ck = unionmultij∈fromk(Uj\
Sj) unionmulti (Vk \ Sk) we get:
P(Ck,FH) =
∑
{X1,...,Xn}\Ck
∏
Xi∈{X1,...,Xn}
Ki
(
Xi|Xpai
)
= Φk(Ck)
∏
j∈fromk
∑
Uj\Sj
∑
Vk\Sk
∏
Xi∈U∗j
Ki
(
Xi|Xpai
) ∏
Xi∈V ∗k
Ki
(
Xi|Xpai
)
= Φk(Ck)
∏
j∈fromk
∑
Uj\Sj
∏
Xi∈U∗j
Ki
(
Xi|Xpai
)
︸ ︷︷ ︸
Fj(Sj)
∑
Vk\Sk
∏
Xi∈V ∗k
Ki
(
Xi|Xpai
)
︸ ︷︷ ︸
Bk(Sk)
.
The factorisation being possible as unionmultij∈fromk(Uj \ Sj) ∩ (Vk \ Sk) = ∅ (running
intersection) and ∀j,∀k, U∗j ⊆ Uj and V ∗k ⊆ Vk.
Finally, the recursive expression of the forward and backward quantities can
be easily derived from equations (6) and (7):
P(Sk,FH) =
∑
Ck\Sk
P(Ck,FH)
Fk(Sk)
Bk(Sk) =
∑
Ck\Sk
∏
j∈fromk
Fj(Sj)× Φk(Ck)×Bk(Sk)
which gives the forward recursion by simplifying the Bk(Sk) term.
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B Proofs for the Disease Risk Section
Proof of Theorem 2. For clarity, we recall that S0(t) = P(Ti > t|Xi = 00), S1(t) =
P(Ti > t|Xi 6= 00), pi = P(Xi 6= 00|FH, Ti > τ) and S(t) = P(Ti > t|FH, Ti >
τ), for i = 1, . . . , n, and that {Ti > τ} ⊂ FH. Since the Ti are independent
conditionally to the Xi, the distribution of Ti conditionally on Xi obviously does
not depend on FH (for values of Xi which are not forbidden by FH). This is why
FH can be omitted almost everywhere in the following proof as soon as pi has been
computed.
We have S(t) =
∑
Xi
P(Ti > t,Xi|Ti > τ,FH), where the notation
∑
Xi
repre-
sents the summation over the different possible values of Xi, that is Xi = 00 or
Xi 6= 00. Using Bayes’ rule,
P(Ti > t,Xi 6= 00|Ti > τ,FH) = P(Ti > t|Xi 6= 00, Ti > τ,FH)× P(Xi 6= 00|Ti > τ,FH)
=
P(Ti > t,Xi 6= 00,FH)
P(Ti > τ,Xi 6= 00,FH) × pi
=
P(Ti > t|Xi 6= 00,FH)
P(Ti > τ |Xi 6= 00,FH) × pi =
S1(t)
S1(τ)
pi,
where we used the fact that P(Ti > t|Xi 6= 00,FH) = P(Ti > t|Xi 6= 00). We
similarly prove that P(Ti > t,Xi = 00|Ti > τ,FH) = (1− pi)S0(t)/S0(τ).
The next result is proved using Bayes’ rule:
P(Xi 6= 00|FH, Ti > t) = P(Xi 6= 00,FH, Ti > t)P(FH, Ti > t)
=
P(Ti > t|Xi 6= 00, Ti > τ)
P(Ti > t|FH, Ti > τ) P(Xi 6= 00|FH, Ti > τ),
where we also used the fact that P(Ti > t|Xi 6= 00,FH, Ti > τ) = P(Ti > t|Xi 6=
00, Ti > τ).
We then directly have P(Ti > t|Xi 6= 00, Ti > τ) = S1(t)/S1(τ) from Bayes’
rule, P(Xi 6= 00|FH, Ti > τ) = pi and P(Ti > t|FH, Ti > τ) = S(t) which concludes
the proof.
Finally, in order to prove Equation (5), we recall that
λ(t) = lim
∆t→0
P(t ≤ Ti < t+ ∆t|Ti ≥ t,FH)
∆t
λ0(t) = lim
∆t→0
P(t ≤ Ti < t+ ∆t|Ti ≥ t,Xi = 00)
∆t
λ1(t) = lim
∆t→0
P(t ≤ Ti < t+ ∆t|Ti ≥ t,Xi 6= 00)
∆t
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Then,
P(t ≤ Ti < t+ ∆t|Ti ≥ t,FH) =
∑
Xi
P(t ≤ Ti < t+ ∆t,Xi|Ti ≥ t,FH)
=
∑
Xi
P(t ≤ Ti < t+ ∆t,Xi,FH)/P(Ti ≥ t,FH)
=
∑
Xi
P(t ≤ Ti < t+ ∆t|Xi)P(Xi|Ti ≥ t,FH),
using Bayes’ rule and the fact that P(t ≤ Ti < t + ∆t|Xi,FH) = P(t ≤ Ti <
t + ∆t|Xi) and P(Xi,FH|Ti ≥ t,FH) = P(Xi|Ti ≥ t,FH). Dividing by ∆t and
taking the limit as ∆t tends to 0 gives
λ(t) = λ1(t)× P(Xi 6= 00|Ti ≥ t,FH) + λ0(t)× P(Xi = 00|Ti ≥ t,FH)
We showed previously that P(Xi 6= 00|Ti ≥ t,FH) = piS1(t)/(S(t)S1(τ)) and
P(Xi = 00|Ti ≥ t,FH) = (1− pi)S0(t)/(S(t)S0(τ)) which concludes the proof.
Proof of Lemma 3. The first part of the equality is a standard result in the com-
peting risk setting: we have, from Bayes’ rule,
λα(u) = lim
∆t→0
P(t ≤ Ti < t+ ∆t|FH)
∆tP(T ∗i ≥ t|FH)
and consequently λα(u)Sβ(u) is equal to the density of T conditionally to FH.
Then, since λα(u) = αj for u ∈]cj−1, cj] we have
P(Ti ≤ t|Ti > cj−1,FH) =
∫ t
cj−1
λα(u)Sβ(u)du = αj
∫ t
cj−1
Sβ(u)du
= αj
∫ t
cj−1
exp
(
−
∫ u
0
λβ(v)dv
)
du
Now, for u ∈]cj−1, t], t ≤ cj,∫ u
0
λβ(v)dv =
∫ cj−1
0
λβ(v)dv + βj(u− cj−1)
and∫ t
cj−1
exp
(
−
∫ u
0
λβ(v)dv
)
du = exp
(
−
∫ cj−1
0
λβ(v)dv
)∫ t
cj−1
exp(−βj(u− cj−1))du
= Sβ(cj−1)
∫ t
cj−1
exp(−βj(u− cj−1))du
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The integral on the right side of the equation is straightforward to compute. This
gives,
Sβ(cj−1)
∫ t
cj−1
exp(−βj(u− cj−1))du = 1
βj
(
Sβ(cj−1)− Sβ(cj−1) exp(−βj(t− cj−1))
)
Finally, we conclude by noticing that
Sβ(t) = exp
(
−
∫ cj−1
0
λβ(u)du−
∫ t
cj−1
λβ(u)du
)
= Sβ(cj−1) exp (−βj(t− cj−1))
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